Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review.

Advances in Therapy
Caterina ArruPanagiotis Paliogiannis

Abstract

Cancer immunotherapy represents one of the most important innovations in modern medicine. Durvalumab is an anti-programmed cell death ligand 1 (PDL-1) agent which is currently under investigation in several studies in combination with the anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) drug tremelimumab. The aim of this review was to systematically identify and revise the current scientific literature investigating the combination of these two drugs in solid tumors. A digital search on the Medline (PubMed interface) and Scopus databases for articles published from inception to 26 February 2021 was performed. The terms used for the search were durvalumab AND tremelimumab. Trials reported in English involving adult patients with solid cancers treated with the combination durvalumab plus tremelimumab were retrieved; the references of the articles were cross-checked to identify missing papers. The electronic search produced 267 results; after exclusion of duplicates, irrelevant articles, reviews, and papers not in English or missing data, 19 articles were included for revision. The total number of patients treated with the combination of durvalumab and tremelimumab in the studies retrieved was 2052. The combination of dur...Continue Reading

References

Mar 22, 1996·Science·D R LeachJ P Allison
Feb 7, 2002·The European Respiratory Journal·E BrambillaY Shimosato
Feb 18, 2004·International Journal of Radiation Oncology, Biology, Physics·Sandra DemariaSilvia C Formenti
Dec 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carmelo BlanquicettMartin R Johnson
Jun 19, 2007·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Hyun-Mi BaeDae Seog Heo
Sep 12, 2008·The New England Journal of Medicine·Jan B VermorkenRicardo Hitt
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ki Y ChungLeonard B Saltz
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B Vermorken, P Specenier
Nov 4, 2010·Archives of Pathology & Laboratory Medicine·William D Travis
Mar 23, 2011·Nature Reviews. Clinical Oncology·Ralph R Weichselbaum, Samuel Hellman
Aug 11, 2012·European Urology·Maximilian BurgerYair Lotan
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler
Jul 20, 2014·International Immunology·Christian U Blank, Alexander Enk
Sep 10, 2014·Oncology Letters·Panagiotis PaliogiannisGrazia Palomba
Sep 23, 2014·Cancer Immunology, Immunotherapy : CII·Luana CalabròMichele Maio
Oct 23, 2014·Cancer·Lauren Averett Byers, Charles M Rudin
Jul 15, 2015·British Journal of Cancer·C D FankhauserP K Bode
Nov 26, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Z CiernaP Babal
Dec 17, 2015·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Lindsey A TorreAhmedin Jemal
Jan 9, 2016·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Sep 25, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J W ValleUNKNOWN ESMO Guidelines Committee
Oct 26, 2016·JCI Insight·Rajarsi MandalLuc Gt Morris
Dec 3, 2016·European Respiratory Review : an Official Journal of the European Respiratory Society·Anna C BibbyIoannis Psallidas
Dec 14, 2016·World Journal of Gastroenterology : WJG·Milena Ilic, Irena Ilic
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 28, 2017·Scientific Reports·Michiru NishitaYasuhiro Minami
Sep 9, 2017·The New England Journal of Medicine·Scott J AntoniaUNKNOWN PACIFIC Investigators
Mar 16, 2018·International Journal of Cancer. Journal International Du Cancer·Antonio FaddaPatrizia Zavattari
Mar 24, 2018·Science·Antoni Ribas, Jedd D Wolchok
Jun 28, 2018·Cancer Immunology, Immunotherapy : CII·Carlo PutzuPanagiotis Paliogiannis
Jul 24, 2018·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Jiyun LeeJong-Mu Sun
Oct 4, 2018·The New England Journal of Medicine·Scott J AntoniaUNKNOWN PACIFIC Investigators
Dec 24, 2018·The New England Journal of Medicine·Thierry ConroyUNKNOWN Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group
Feb 1, 2019·Immunotherapy·Ariana Nicole RenrickAnil Shanker
Feb 13, 2019·Medicina·Maria Maddalena SimilePanagiotis Paliogiannis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.